Eyeworld Daily News

3 EW SHOW DAILY ASCRS•ASOA Symposium & Congress, New Orleans 2016 the American Intraocular Implant Society, the American Academy of Ophthalmology, the Michigan State Medical Society, and the Interna- tional Intraocular Lens Implant Society. Hiroko Bissen-Miyajima, MD, PhD, is department chair and professor of ophthalmology at Tokyo Dental College Suidobashi Hospital, Tokyo. She specializes in cataract and refractive surgery. Over her 20-year career, she has built a reputation as a skillful surgeon, well known around the globe as a major investigator for multifocal intraocu- lar lenses and for leading the way in femtosecond laser-assisted cataract surgery. Dr. Bissen-Miyajima is a regular reviewer for several presti- gious medical journals and holds memberships in many professional medical associations including the Japanese Ophthalmological Society, the American Academy of Ophthal- mology, and the European Society of Cataract & Refractive Surgeons, continued from page 1 Mobile phone technology is another area being used to increase medication compliance. For exam- ple, medication reminder apps, live video interfaces with pharmacy staff, and even the use of rewards for tak- ing medications are all having some success. Some practices are designing apps that communicate with pa- tients via mobile technology to help remind them when to take medica- tion, Dr. Krishna said. One such app has been designed by the Singapore National Eye Centre. Punctal plug delivery of glaucoma meds and other approaches Two punctal plug approaches that provide the sustained release of latanoprost—the Punctal Plug De- livery System (Mati, Austin, Texas) and Dextenza (Ocular Therapeu- tix, Bedford, Massachusetts)—can last for up to 3 months and have a retention rate of 95%, said Richard Lewis, MD, Sacramento, California. Dextenza is slated for U.S. Food and Drug Administration approval in July. Another unique approach to drug delivery is gel eye drops, which Dr. Lewis described as a "very inves- tigational concept" that are not yet studied in humans. The drops turn into a stable gel and release in the eye for up to a month. Other long-term approaches that are studied now include sub- conjunctival inserts and drug-elut- ing contact lenses. Clinicians must consider that these approaches are not ideal for all medications, especially prostaglan- dins. They also take a long time to research, and few of these products have undergone peer review, Dr. Lewis said. More innovative approaches to glaucoma drug delivery Ninety percent of patients easily tol- erated the Helios bimatoprost ocular insert (ForSight VISION5, Menlo Park, California), according to phase 2 study results just published this week in the journal Ophthalmology. "This is the first trial to show an intraocular pressure reduction can be sustained up to 13 months," said James Brandt, MD, Davis, Califor- nia. The insert is replaced every 6 months by the physician. Although there is a risk that the device will fall out, it can be easily reinserted. Phase 3 trials are now upcoming, and the company is also starting a phase 1 trial to test the combined delivery of timolol and bimatoprost. Yet another approach under de- velopment is the use of intracameral delivery of glaucoma medication, said Mark Packer, MD, Boulder, Colorado. Intracameral delivery requires less frequent medication dosing and does not have any ocular surface compromise. However, there may be a risk for infections over time, and the long-term effects on the corneal endothelium are not yet clear, he cautioned. Also, clinicians may want to have these patients re- turn to the office monthly to ensure there are no intraocular pressure spikes, he advised. EAGLE trial on cataract surgery in glaucoma results not yet ready Anjali Bhorade, MD, St. Louis, said that results from the EAGLE study on the use of lens extraction to treat patients with primary angle closure glaucoma are not yet ready. For now, if a patient with angle closure glaucoma has a visually significant cataract, lens extraction may be appropriate, she said. However, if it's a non-visually significant cataract, lens extraction may not be appro- priate unless the patient's glaucoma is medically uncontrolled. Clini- cians are awaiting results from the EAGLE trial to help determine the best course of treatment for these patients, Dr. Bhorade said. Glaucoma Day covered a wide range of topics, including imaging, angle closure glaucoma, surgical glaucoma, and video presentations. Ronald Fellman, MD, Dallas, gave the 2016 Stephen A. Obstbaum, MD, Honored Lecture on canal surgery. EW Editors' note: Dr. Brandt has financial interests with ForSight VISION5. Dr. Krishna has financial interests with Cloud Nine Development. Dr. Lewis has financial interests with Aerie Phar- maceuticals (Bedminster, New Jersey), Alcon (Fort Worth, Texas), Allergan (Dublin), and various other ophthalmic companies. Dr. Packer has financial interests with Aerie Pharmaceuticals, Alcon, Bausch + Lomb (Bridgewater, New Jersey), and various other oph- thalmic companies. Dr. Bhorade has no financial interests related to her presentation. continued from page 1 Past Honored Guests • Philippe Sourdille, MD (2015) • Marcelo Ventura, MD, PhD (2015) • Philip Hessburg, MD (2014) • Keiki Mehta, MD (2014) • Jeo Ho Kim, MD (2013) • Harold Stein, MD (2013) • Bo Philipson, MD, PhD (2012) • John Darin, MD (2012) • Ulf Stenevi, MD (2011) • Gavin Herbert (2011) • Paul Honan, MD (2010) • Emanuel Rosen, FRCS, FRCOphth (2010) • Miguel Angelo Padilha, MD (2009) • Patrick Ian Condon, MB (2009) • John Shepherd, MD, FACS (2008) • Karl Jacobi, MD (2008) • Eric Arnott, MD (2007) • Jared Emery, MD (2007) • H. Dunbar Hoskins Jr., MD (2006) • Thomas Mazzocco, MD (2006) • Richard Kratz, MD (2005) • Malcolm McCannel, MD (2004) among others. She is president of the Japanese Society of Cataract and Refractive Surgery, past president and 2013 Medal Awardee of the International Intraocular Implant Club, and she was the Asia-Pacific Association of Cataract & Refractive Surgeons 2011 Lim Lecture Awardee. EW The winner of Friday's EyeWorld event drawing is: Himani Goyal, MD, Brooklyn, New York

• Cover